Severe eosinophilic asthma

Active Ingredient: Mepolizumab

Indication for Mepolizumab

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Adjunct intent

Mepolizumab is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.

For this indication, competent medicine agencies globally authorize below treatments:

100 mg once every 4 weeks

For:

Dosage regimens

Subcutaneous, 100 milligrams mepolizumab, once every 4 weeks.

Detailed description

The recommended dose of mepolizumab is 100 mg administered subcutaneously once every 4 weeks.

Mepolizumab is intended for long-term treatment. The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient’s disease severity and level of control of exacerbations.

Dosage considerations

Mepolizumab is for subcutaneous injection only and should be administered by a healthcare professional. It may be injected into the upper arm, thigh, or abdomen.

For doses which require more than one injection, it is recommended that each injection is administered at least 5 cm apart.

40 mg once every 4 weeks

For:

Dosage regimens

In case that patient age in years is ≥ 6, subcutaneous, 40 milligrams mepolizumab, once every 4 weeks.

Detailed description

Children aged 6 to 11 years old

The recommended dose of mepolizumab is 40 mg administered subcutaneously once every 4 weeks.

Mepolizumab is intended for long-term treatment. The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient’s disease severity and level of control of exacerbations.

Dosage considerations

Mepolizumab is for subcutaneous injection only and should be administered by a healthcare professional. It may be injected into the upper arm, thigh, or abdomen.

For doses which require more than one injection, it is recommended that each injection is administered at least 5 cm apart.

Active ingredient

Mepolizumab

Mepolizumab is a humanised monoclonal antibody (IgG1, kappa), which targets human interleukin-5 (IL-5) with high affinity and specificity. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophils. Mepolizumab is indicated as an add-on treatment for severe refractory eosinophilic asthma.

Read more about Mepolizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.